Potentiation of the Vincristine Effect on P388 Mouse Leukemia Cells by a Newly Synthesized Dihydropyridine Analogue, PAK-200
Overview
Affiliations
A newly synthesized dihydropyridine analogue, 2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2-dioxaphosphorina n-2-yl)-1- (2-morpholinoethyl)-4-(3-nitrophenyl)-3-pyridinecarboxylate (PAK-200), at 1 microM completely reversed the resistance to vincristine in vincristine-resistant P388 mouse leukemia cells (P388/VCR), in vitro. PAK-200 at 2 microM inhibited the efflux of [3H]vincristine from P388/VCR and increased the accumulation of [3H]vincristine in P388/VCR to a level similar to that in P388 cells. P-Glycoprotein in membrane vesicles from P388/VCR cells was photolabeled with [3H]azidopine. The labeling was completely inhibited by 10 microM PAK-200. The calcium antagonistic activity of PAK-200 was about 1000 times lower than that of another dihydropyridine analogue, nicardipine. Experiments with P388 and P388/VCR-bearing mice showed that PAK-200 enhanced the effect of vincristine on both leukemia cells in vivo. These results suggest that PAK-200 interacts with P-glycoprotein and reverses drug resistance in P388 mouse leukemia cells in vitro, and that PAK-200 has an ability to potentiate the effect of vincristine on P388 mouse leukemia cells in vivo.
Namekata I, Tamura M, Kase J, Hamaguchi S, Tanaka H Biomolecules. 2023; 13(12).
PMID: 38136589 PMC: 10741401. DOI: 10.3390/biom13121719.
Zhang D, Satake M, Fukuzawa S, Sugahara K, Niitsu A, Shirai T J Nat Med. 2011; 66(1):222-6.
PMID: 21792727 DOI: 10.1007/s11418-011-0565-3.